Neurophysiopathological aspects of paclitaxel-induced peripheral neuropathy
R Velasco-González, U Coffeen - Neurotoxicity research, 2022 - Springer
Chemotherapy is widely used as a primary treatment or adjuvant therapy for cancer. Anti-
microtubule agents (such as paclitaxel and docetaxel) are used for treating many types of …
microtubule agents (such as paclitaxel and docetaxel) are used for treating many types of …
α-Conotoxin RgIA and oligoarginine R8 in the mice model alleviate long-term oxaliplatin induced neuropathy
IA Dyachenko, YA Palikova, VA Palikov, YV Korolkova… - Biochimie, 2022 - Elsevier
Оligoarginines were recently discovered (Lebedev et al., 2019 Nov) as a novel class of
nicotinic acetylcholine receptors (nAChRs) inhibitors, octaoligoarginine R8 showing a …
nicotinic acetylcholine receptors (nAChRs) inhibitors, octaoligoarginine R8 showing a …
Naturally occurring glucosinolates and isothiocyanates as a weapon against chronic pain: potentials and limits
E Lucarini, L Micheli, L Di Cesare Mannelli… - Phytochemistry …, 2022 - Springer
Investigation into glucosinolates (GLs) therapeutic effects boasts a long history, which began
with the evidence that their hydrolysis-derived isothiocyanates (ITCs) could exert …
with the evidence that their hydrolysis-derived isothiocyanates (ITCs) could exert …
Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A/POLAR-M)
P Pfeiffer, M Lustberg, J Näsström… - JNCI Cancer …, 2022 - academic.oup.com
Abstract Background Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing
patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized …
patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized …
Preclinical evidence for mitochondrial DNA as a potential blood biomarker for chemotherapy-induced peripheral neuropathy
A Trecarichi, NA Duggett, L Granat, S Lo, AN Malik… - Plos one, 2022 - journals.plos.org
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious dose-limiting side effect
of several first-line chemotherapeutic agents including paclitaxel, oxaliplatin and …
of several first-line chemotherapeutic agents including paclitaxel, oxaliplatin and …
[HTML][HTML] Electroacupuncture attenuates spared nerve injury-induced neuropathic pain possibly by promoting the progression of AMPK/mTOR-mediated autophagy in …
Y Cui, C Hu, C Niu, M He, X Qiu, Q Yao… - Annals of Translational …, 2022 - ncbi.nlm.nih.gov
Background Neuropathic pain (NP) is a syndrome that arises from central or peripheral
nerve injury, which manifests primarily as hyperalgesia, spontaneous pain, and allodynia …
nerve injury, which manifests primarily as hyperalgesia, spontaneous pain, and allodynia …
A systematic review and meta-analysis of the effectiveness of neuroprotectants for paclitaxel-induced peripheral neuropathy
Background Paclitaxel-induced peripheral neuropathy (PIPN) is a disabling side effect of
paclitaxel with few effective preventive strategies. We aim to determine the efficacy of …
paclitaxel with few effective preventive strategies. We aim to determine the efficacy of …
Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice
A Al-Romaiyan, W Masocha - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Triterpenes such as euphol and pristimerin, which are plant secondary
metabolites, were the first to be characterized as monoacylglycerol lipase (MAGL) inhibitors …
metabolites, were the first to be characterized as monoacylglycerol lipase (MAGL) inhibitors …
Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and …
Background The use of oxaliplatin in digestive tract cancers could induce severe peripheral
neuropathy (OIPN) decreasing the quality of life of patients and survivors. There is currently …
neuropathy (OIPN) decreasing the quality of life of patients and survivors. There is currently …
Using geriatric assessment to guide conversations regarding comorbidities among older patients with advanced cancer
AS Kleckner, M Wells, LA Kehoe, NJ Gilmore… - JCO Oncology …, 2022 - ascopubs.org
PURPOSE: Older patients with advanced cancer often have comorbidities that can worsen
their cancer and treatment outcomes. We assessed how a geriatric assessment (GA) …
their cancer and treatment outcomes. We assessed how a geriatric assessment (GA) …